A Phase I, Randomised, Double-blind (Sponsor Open), Placebo-Controlled Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330811 in Healthy Subjects

Trial Profile

A Phase I, Randomised, Double-blind (Sponsor Open), Placebo-Controlled Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330811 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

At a glance

  • Drugs GSK 2330811 (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 05 Jan 2016 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 03 May 2015 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top